预约演示
Teva snares up to $150M in Abingworth funding to propel late-stage asthma rescue inhaler
抗体药物偶联物引进/卖出
For Abingworth, the Teva deal follows another similar accord with Gilead Sciences on an antibody-drug conjugate cancer medicine.
ShorAbingworthGilead Sciences teamed up with Carlyle’s Abingworth Gilead Sciences research on its antibody-drug cancerate Trodelvy, Teva is following a similar pathway with an asthma rescue inhaler.
Monday, Teva aGilead Sciencesevealed that they have entAbingworthnical collaboration agreement to advance TEV-’248, a dualTrodelvycombination of an inhaled corticosteroid and aasthma-acting beta-agonist (ICS/SABA). In a release, the companies said the prospect could become the first ICS/SABA for both the adult and pediatric patient population.
The treaTevat comAbingworthicasone propionate and albuterol sulfate and is delivered through Teva's breath-activated, multi-dose dry powder inhaler. The drug is currently in late-stage testing.
Under the deal, Abingwofluticasone propionatewith albuterol sulfaten to offset R&D costs for the program. Launch Therapeutics, a development company backed by Abingworth and Carlyle, will take charge of executing clinical trials.
Teva, for its paAbingworthontinue to be Tevaharge of manufacturing, regulatory interactions and potential Launch Therapeuticsthe companies said.Abingworth
Tevahe drug wins FDA approval, Abingworth will be eligible for fixed payments and royalties based on sales.
The deal comes asFDAva works to implement CEO Richard Francis' "Pivot to Growth" strategy. Under the program, the company is emphasizing its pipeline and business development to reduce reliance on generics. Last year, Teva delivered a 6% increase in sales, flipping the script after several years of declines.
As for Abingworth,Teva biopharma investment firm recently entered a similar arrangement with Gilead Sciences. In late February, Abingworth teamed up with Gilead to offer up to $210 million to fund further development oTevaodelvy. Abingworth could be in line for fixed and royalty payments based on future success of the drug in non-small cell lung cancer.
That deAbingworthter a clinical setback for the drug and will help Gilead shoulder costs and Gilead Sciences for further developAbingworthch Therapeutics Gileadolved in that partnership, as well.TrodelvyAbingworthnon-small cell lung cancer
Before that, in August 2022, Launch made its debut as part of a parGileadip that sought to advance Opthera’s wet age-related macular dLaunch Therapeuticste.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。